HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Important Data in the Squamous NSCLC Population

June 2nd 2018

IMPower150: Implications for the Treatment of NSCLC

June 2nd 2018

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

June 2nd 2018

Actual Use of Pembrolizumab and Chemotherapy in NSCLC

June 2nd 2018

KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

June 2nd 2018

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Dr. Mitri Discusses Adjuvant Therapy for HER2+ Breast Cancer

May 31st 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses adjuvant therapy for patients with HER2-postive breast cancer.